Compass Therapeutics (CMPX)

• Market cap: $1.03B
• 1 day: 7.61%
• 5 days: 19.59%
• 1 month: 41.46%
• 3 months: 66.19%
• 6 months: 176.19%
• Year to date: 314.29%
• 1 year: 255.83%
• 5 years: 45.73%
• 10 years: 45.73%
• Sector: Healthcare
• Industry: Biotechnology

About: Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Employees: 35